Previous studies highlighted a detrimental impact of cancer treatments on patients' subjective and objective cognitive
functioning. Among these treatments, chemotherapeutic agents used against lymphoma could have a severe impact on the patients' executive
performances such as planning and managing tasks, speed in processing information, paying attention to and remembering details, and
achieving double tasks. The FDG-PET (Positron Emission Tomography) is non-invasive diagnostic tool that provides metabolic activity
of tissues. Several FDG-PET studies showed an association between a reduced metabolic activity of the brain and various cognitive
deficits in ageing, in mild cognitive impairment, in Parkinson disease or in the first Alzhiemer disease phases. The aim of this
longitudinal study is to assess the links between the executive deficits observed in the first chemotherapy cycles (short-term
memory, working memory, inhibition, selective attention, speed in processing information, flexibility) and changes in the metabolic
activity of the prefrontal cortex assessed with FDG-PET among lymphoma patients in their first line of treatment. Moreover, the aim
of this longitudinal study is to assess the links between these executive deficits and the patients' functional autonomy and
distress.